埃達珠單抗

埃達珠單抗（INN：Etaracizumab；開發代號：MEDI-522），或譯伊瑞西珠單抗，商品名Abegrin，是一種人源化單克隆抗體，正在研究用於治療轉移性黑色素瘤、前列腺癌、^[1]卵巢癌^[2]和各種其他類型的癌症。^[3]它是由MedImmune（英語：MedImmune）生產的。^[1]

它是Vitaxin（英語：Vitaxin）（也稱為MEDI-523）的增強版。兩者均源自小鼠抗體LM609。^[4]

參考資料[編輯]

^ ^1.0 ^1.1 Etaracizumab (PDF). Statement On A Nonproprietary Name Adopted By The Usan Council.
^ Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, et al. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia. November 2008, 10 (11): 1259–67. PMC 2570602 . PMID 18953435. doi:10.1593/neo.08740.
^ Delbaldo C, Raymond E, Vera K, Hammershaimb L, Kaucic K, Lozahic S, et al. Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. Investigational New Drugs. February 2008, 26 (1): 35–43. PMID 17876527. S2CID 37221398. doi:10.1007/s10637-007-9077-0.
^ McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, et al. Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clinical Cancer Research. November 2005, 11 (21): 7851–60. PMID 16278408. doi:10.1158/1078-0432.CCR-05-0262.